Cognitive Function Clinical Trial
Official title:
Cognitive Control and Physical Exercise: A Multi-Modal Intervention
Verified date | August 2015 |
Source | Columbia University |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
The purpose of this study is to test the hypothesis that aerobic exercise and a computer-based cognitive intervention leads to improved cognitive function accompanied by increases in gray matter density and changes in functional magnetic resonance imaging (fMRI) patterns of task-related activation.
Status | Terminated |
Enrollment | 12 |
Est. completion date | June 2015 |
Est. primary completion date | June 2015 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 60 Years to 75 Years |
Eligibility |
Inclusion Criteria: 1. Age 60-75 2. English-speaking 3. Strongly right-handed 4. BMI > 18.5 and < 32 5. Post-menopausal (women only): no estrogen replacement therapy 6. Sedentary: VO2max < 36 ml/kg/min for men age 60-75; < 29 ml/kg/min for women age 60-75 (determined using Jones Formula Men = (60-(0.55*AGE)) Women = (48-(.37*AGE)) Exclusion Criteria: 1. MRI contraindications (e.g., metallic implants, pacemaker, weight > 350 lbs, waist > 55") 2. Hearing impaired/hearing aids, unable to read newspaper at arm's length with corrective lenses 3. Objective cognitive impairment 4. Ischemic changes, abnormal blood pressure responses, or any significant ectopy during aerobic capacity testing 5. Cardiovascular disease 6. Uncontrolled high blood pressure (systolic blood pressure = 180 mmHg; or diastolic blood pressure = 105 mmHg on two measures) 7. Current or recent (evidence of disease x 5 years) non-skin neoplastic disease or melanoma 8. Active hepatic disease (not a history of hepatitis) or primary renal disease requiring dialysis, primary untreated endocrine diseases, e.g., Cushing's disease or primary hypothalamic failure or insulin dependent diabetes (Type I or II). 9. HIV infection 10. Pregnant or lactating (participation allowed 3 months after ceasing lactation 11. Other medical disorders judge to interfere with study 12. Medications that target CNS (e.g., neuroleptics, anticonvulsants, antidepressants, benzodiazepines) within the last month 13. Women: any selective estrogen receptor modulator or aromatase inhibitor Men: androgen ablation/deprivation hormonal therapies 14. Any history of psychosis or electroconvulsive therapy 15. Psychotic disorder (lifetime) 16. Current or recent (within past 12 months) alcohol or substance abuse or dependence. Recent use (past month) of recreational drugs. 17. Brain disorder such as stroke, tumor, infection, epilepsy, multiple sclerosis, degenerative diseases, head injury, mental retardation 18. Imaged cortical stroke or large subcortical lacunae or infarct or space-occupying lesion (= 2 cubic cm). Other findings, e.g., periventricular caps or small white matter hyperintensities, do not result in exclusion 19. Diagnosed learning disability, dyslexia |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science
Country | Name | City | State |
---|---|---|---|
United States | Columbia University Medical Center | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Columbia University | National Institute on Aging (NIA) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes in measures of executive control function and episodic memory at 6 months | tests of global intelligence, executive function, working memory and processing speed | Baseline and 12 weeks | No |
Secondary | Changes in brain structure, resting cerebral blood flow and network efficiency at 6 months | structural MRI (for gray matter density), resting CBF (arterial spin labeling) and cognitive activation fMRI studies | Baseline and 12 weeks | No |
Secondary | Change in aerobic capacity at 6 months | aerobic capacity as measured by VO2 max | Baseline and 12 weeks | No |
Secondary | Changes in measures of executive control function and episodic memory at 1 year | tests of global intelligence, executive function, working memory and processing speed | Baseline and 52 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05563805 -
Exploring Virtual Reality Adventure Training Exergaming
|
N/A | |
Completed |
NCT03708692 -
Menstrual Cycle Phases on Recovery and Cognitive Function
|
||
Active, not recruiting |
NCT04505345 -
Virtual Reality Cognitive Training in Alcohol Use Disorder
|
N/A | |
Completed |
NCT04430465 -
Effects of Wholegrains on Children's Health (KORN)
|
N/A | |
Completed |
NCT02915913 -
Effects of Exercise Training on Cognitive Function and Neurotrophic Factors in Overweight Adults
|
N/A | |
Completed |
NCT01410097 -
Physical and Cognitive Function - Look AHEAD Ancillary Study
|
N/A | |
Completed |
NCT03826121 -
Efficacy and Safety of Sesame Oil Cake Extract on Improvement of Cognitive Function
|
N/A | |
Recruiting |
NCT05621278 -
Children to Adults Mental and Psychosomatic Health Study (CAMPS)
|
||
Completed |
NCT05498415 -
Feasibility, Acceptability, and Efficacy of the Sleep Move Stand Study
|
N/A | |
Completed |
NCT03208569 -
Anticholinergic Burden - Treatment Optimization
|
||
Completed |
NCT03793777 -
The Effect of Aronia Melanocarpa Extract on Cognitive Function
|
N/A | |
Recruiting |
NCT05525299 -
Reminiscence-Based Life Review on Copying With Existential Suffering Among Older Cancer Survivors
|
N/A | |
Completed |
NCT03698123 -
Performance Nutrition for Residents and Fellows
|
N/A | |
Completed |
NCT04543500 -
Self-regulation of Prefrontal Cortex During Emotional Cognitive Control
|
N/A | |
Recruiting |
NCT05891977 -
Effect of Tomato Paste Consumption on the Microbiota-gut-brain Axis in Healthy Adults
|
N/A | |
Recruiting |
NCT05591885 -
Nutrilite Memory Builder on the Improvement of Cognitive Function
|
N/A | |
Active, not recruiting |
NCT05575752 -
Acute Health Effects of High Temperature Exposure
|
N/A | |
Completed |
NCT03716609 -
Effects of Magnesium Supplementation on Hemodynamic Parameters and Cognitive Function
|
N/A | |
Completed |
NCT02763514 -
The Effects of DHA- and EPA-enriched Oils on Cognitive Function and Mood
|
N/A | |
Completed |
NCT02675621 -
Investigation of Acute Mood and Cognitive Performance Effects of Beverages Containing Phenolics in Healthy Adults
|
N/A |